St. Jude Medical (NYSE:STJ) today announced CE Mark approval in the European Union for its latest in multi-point cardiac pacing, the Quadra Assura MP cardiac synchronization defibrillator.
The new technology gives physicians more fine-tuned options for pulse frequency and pacing sites on the left side of the heart, according to St. Jude. The company added that the device is ideal for patients who do not respond to traditional bi-ventricular pacing treatment.
"Many patients with heart failure have scar tissue on their cardiac anatomy that makes it difficult to provide them with optimal and effective therapy," Carlo Pappone, director of the Department of Arrhythmology at Maria Cecilia Hospital in Italy, said on behalf of the company. "The new MultiPoint Pacing technology helps individualize therapy for each of my patients and potentially allows those patients unable to benefit from traditional cardiac resynchronization therapy to be effectively treated."
The Quadra Assura MP connects with St. Jude’s Quartet leads, which have 4 electrodes to that allow physicians to program simultaneous or sequential pacing and "tailor CRT pacing for each patient."
In April, St. Jude also won CE Mark for its Allure Quadra quadripolar cardiac resynchronization therapy pacemaker, the 1st device of its kind on the European market.
